Research
Hormonal
Lower plasma adiponectin in women with prior GDM is associated with subclinical inflammation, indicated by higher levels of C-reactive protein (CRP) and plasminogen activator inhibitor-1 (PAI-1).
Low adiponectin in women with a history of GDM is linked to higher levels of inflammation markers like CRP and PAI-1. This suggests that the hormonal imbalance contributes to a state of subclinical inflammation, which is a risk factor for cardiovascular disease.
GoodSupportsHIGH confidence
pGDM showed... increased plasma leptin (P < 0.003), PAI-1 (P < 0.002), and CRP (P < 0.03)... plasma adiponectin... correlated negatively with plasma glucose... leptin (P < 0.01), CRP (P < 0.007), and PAI-1 (P < 0.0001).
Why this rating
The correlations are statistically significant (P < 0.007 for CRP, P < 0.0001 for PAI-1) and consistent across the pGDM group.
Source
Plasma Adiponectin, Insulin Sensitivity, and Subclinical Inflammation in Women With Prior Gestational Diabetes Mellitus
Christine Winzer et al. · Diabetes Care · 2004
DOI 10.2337/diacare.27.7.1721
cohort · n=108Cited 181×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Women with prior gestational diabetes mellitus (pGDM) exhibit significantly lower plasma adiponectin concentrations compared to women with normal glucose tolerance (NGT), independent of body fat mass and insulin sensitivity.Good
- In insulin-resistant women with prior GDM, plasma adiponectin levels decrease further over a 1-year follow-up period, even in the absence of changes in body weight, body fat composition, or glucose tolerance.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →